Weidmann B, Hoffmann W, Seeber S
Zentrum für Innere Medizin, Städtisches Krankenhaus Leverkusen.
Onkologie. 1990 Jun;13(3):217-20. doi: 10.1159/000216762.
We report on 6 male patients with advanced renal cell carcinoma without prior chemotherapy. They were treated by recombinant alpha 2-interferon in a toxicity limited dosage. The maximal tolerated dose was 3 x 5 x 10(6) U/wk. to 3 x 20 x 10(6) U/wk., limited by flu-like symptoms in 5 cases, by thrombopenia in 1. We observed a response in 3 cases (2 partial remissions, 1 mixed response) lasting for 10, 11 and 13 months, respectively. This comparatively good result may be due to patient characteristics (little pretreatment, pulmonary metastasis, good performance status) as well as to a medium dosage. Occurrence of response after termination of interferon therapy in two cases are of particular interest.
我们报告了6例未曾接受过化疗的晚期肾细胞癌男性患者。他们接受了重组α2干扰素治疗，剂量以毒性为限。最大耐受剂量为每周3×5×10⁶单位至3×20×10⁶单位，5例受流感样症状限制，1例受血小板减少限制。我们观察到3例有反应（2例部分缓解，1例混合反应），分别持续10、11和13个月。这一相对较好的结果可能归因于患者特征（预处理少、肺转移、良好的身体状况）以及中等剂量。两例在干扰素治疗终止后出现反应尤其令人关注。
